Clinical Trial Search

Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease — 362.7; 429.1; 420.2; 200.9 titer

Primary: Percentage of Subjects With at Least One Adverse Event (AE) From First Certolizumab Pegol (CZP) Dose up to Approximately 7 Years — 94.9 percentage of participants

Primary: mITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit — 15; 8 participants

Primary: Percentage of Subjects With at Least One Adverse Event (AE) From First Certolizumab Pegol (CZP) Dose up to Approximately 6.8 Years — 89.1 percentage of participants

Primary: Pain: Visual Analog Scale — -2.3; 1.4; -9.2; 2.6 mm — p=0.03

Primary: The Number of Participants Experiencing Adverse Events — 46; 42; 88; 160 Participants

Primary: Progression-Free Survival (PFS) — 4.28; 3.91 months — p=0.1933

Primary: Percentage Change SIGH SAD Depression Rating — -36.4; -52.7 percentage of change on SIGH SAD — p=0.014

Primary: Total Number of Blood Components Transfused During and up to 24 Hours Post Operatively — 68.9; 87.2; 0; 4.1 units of blood components

Primary: Skeletal-related Event-free Survival in Men With Bone Metastases From Prostate Cancer — 58; 49; 201; 214 participants

Primary: Change From Baseline in Number of Daily Episodes of Urinary Incontinence — 5.47; 5.09; -2.65; -0.87 Incontinence episodes

Primary: Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series…

Primary: Change From Baseline in Number of Daily Episodes of Urinary Incontinence — 5.52; 5.70; -2.95; -1.03 Incontinence episodes

Primary: Percent Change in Truncal Lesion Counts — 52.1; -9.2; 53.2; 18.2 percentage change of lesions

Primary: Number of Participants With Relapse-Free Response at 1 Year — 10; 10 participants